iiinova — where your digital self keeps evolving

Hans-Joachim Anders @hjanders.bsky.social · 30/10/2025

Now open access in @ndt-era.bsky.social Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD 🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors ▶️ academic.oup.com/ndt/article/...

010

Hans-Joachim Anders @hjanders.bsky.social · 28/10/2025

Now open access in @ndt-era.bsky.social Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts 🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants ▶️ academic.oup.com/ndt/article-...

020

Hans-Joachim Anders @hjanders.bsky.social · 28/10/2025

Now online in @ndt-era.bsky.social Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival 🧐NTI should prompt the search for urinary tract infection and rejection ▶️ academic.oup.com/ndt/article-...

010

Hans-Joachim Anders @hjanders.bsky.social · 08/10/2025

Now open access in @ndt-era.bsky.social How can we target the production of pathogenic IgA in IgAN? 🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262

021

Hans-Joachim Anders @hjanders.bsky.social · 30/09/2025

Now online in @ndt-era.bsky.social Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI 🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury. ▶️ academic.oup.com/ndt/article-...

032

Hans-Joachim Anders @hjanders.bsky.social · 28/09/2025

Now open access in @ndt-era.bsky.social Prevalence of Strongyloides stercoralis in HD pts in Vienna 🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe. ▶️ academic.oup.com/ndt/article/...

021

Hans-Joachim Anders @hjanders.bsky.social · 27/09/2025

Now open access in @ndt-era.bsky.social QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD 🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915

000

Hans-Joachim Anders @hjanders.bsky.social · 18/09/2025

Now open access in @NDTsocial Anti-GBM disease - Treatment Standard 🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment ▶️ academic.oup.com/ndt/article/...

143

Hans-Joachim Anders @hjanders.bsky.social · 16/09/2025

Now open access in @ndt-era.bsky.social Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations 🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D. ▶️ academic.oup.com/ndt/article/...

000

Hans-Joachim Anders @hjanders.bsky.social · 14/09/2025

Now open access in @ndt-era.bsky.social al CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA 🧐Check also our 2 open access editorials on this innovative concept. ▶️ academic.oup.com/ndt/article/...

130

Hans-Joachim Anders @hjanders.bsky.social · 12/09/2025

Now online in @ndt-era.bsky.social Transition of pts with hereditary nephropathies from pediatric to adult care from WG Genes&Kidney of ERA and ESPN 🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD. ▶️ academic.oup.com/ndt/article-...

031

Hans-Joachim Anders @hjanders.bsky.social · 12/09/2025

New RCT online in @ndt-era.bsky.social Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade 🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN ▶️ academic.oup.com/ndt/article-...

110

Hans-Joachim Anders @hjanders.bsky.social · 08/09/2025

Now open access in @ndt-era.bsky.social Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD 🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD. ▶️ academic.oup.com/ndt/article/...

000

Hans-Joachim Anders @hjanders.bsky.social · 16/08/2025

Now open access in @ndt-era.bsky.social Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications 🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies ▶️ academic.oup.com/ndt/article/...

0188

Hans-Joachim Anders @hjanders.bsky.social · 13/08/2025

Now open access in @ndt-era.bsky.social What do RCTs teach us about the pathophysiology of human IgAN? 🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever. ▶️ academic.oup.com/ndt/article/...

041

Hans-Joachim Anders @hjanders.bsky.social · 12/08/2025

Now online in @ndt-era.bsky.social Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease 🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD ▶️ academic.oup.com/ndt/article-...

022

Hans-Joachim Anders @hjanders.bsky.social · 11/08/2025

Now open access in @ndt-era.bsky.social Evolving strategies for early diagnosis, proactive prevention and treatment of CKD 🧐"Inferior doctors provide KRT Mediocre doctors treat CKD Superior doctors prevent kidney disease" ▶️ academic.oup.com/ndt/article/...

010

Hans-Joachim Anders @hjanders.bsky.social · 13/07/2025

Now online in @ndt-era.bsky.social Acute post-streptococcal GN (in children) - treatment standard 🧐 Pathophysiology, diagnosis, outcome prediction, and management standard ▶️ academic.oup.com/ndt/article-...

020

Hans-Joachim Anders @hjanders.bsky.social · 12/07/2025

Now online in @ndt-era.bsky.social Multifactorial chronic kidney disease 🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions ▶️ academic.oup.com/ndt/article-...

020

Hans-Joachim Anders @hjanders.bsky.social · 12/07/2025

Now online in @ndt-era.bsky.social Treatment standard: CKD in the geriatric patient 🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis ▶️ academic.oup.com/ndt/article-...

020

Hans-Joachim Anders @hjanders.bsky.social · 18/06/2025

The new Impact factors are out. Here is a list of some kidney journals @ndt-era.bsky.social

020

Hans-Joachim Anders @hjanders.bsky.social · 17/06/2025

Ongoing discussion about UACR or UPCR in GN captured in @ndt-era.bsky.social The use of UACR or UPCR for risk prediction in IgAN url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452 UACR predicts kidney events in IgAN url:https://academic.oup.com/ndt/article/40/3/465/7660570

132

Hans-Joachim Anders @hjanders.bsky.social · 05/06/2025

Now first late breaker clinical trial session at #ERA2025

010

Hans-Joachim Anders @hjanders.bsky.social · 03/06/2025

Now open access in @ndt-era.bsky.social Antibody-mediated Rejection - Treatment Standard 🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR. academic.oup.com/ndt/article/...

010

Hans-Joachim Anders @hjanders.bsky.social · 02/06/2025

Now open access in the June edition of @ndt-era.bsky.social Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA 🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD. academic.oup.com/ndt/article/...

010

Hans-Joachim Anders @hjanders.bsky.social · 21/05/2025

Now open access in @NDT-era.bsky.social Individualizing renoprotective therapy in obese pts with CKD 👍Multitarget therapy incl. RASi, SGLT2i, GLP-1ra and nsMRAs improve MACE and MAKE in pts with overweight/obesity and T2DM ▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf069/8129710

000

Hans-Joachim Anders @hjanders.bsky.social · 11/04/2025

Now open access in @ndt-era.bsky.social Maintaining kidney health in aging societies: a JSN and ERA call to action 🧐 Don`t miss the opportunities for intervention doi.org/10.1093/ndt/...

000

Hans-Joachim Anders @hjanders.bsky.social · 24/03/2025

Now online in @ndt-era.bsky.social A new device integrated in the PD cycler for remote monitoring of automated PD. A trial tests whether it will improve clinical outcomes or not. academic.oup.com/ndt/article/...

000

Hans-Joachim Anders @hjanders.bsky.social · 16/03/2025

Now open access on @ndt-era.bsky.social SGLT2 Inhibitors in CKD: Are They Really Effective in All Patients? academic.oup.co

020

Hans-Joachim Anders @hjanders.bsky.social · 26/02/2025

Watch this 3 min author video in @ndt-era.bsky.social by Fernando Fervenza, et al. HCQ for all patients with lupus nephritis?: no academic.oup.com/ndt/article/...

031

Hans-Joachim Anders @hjanders.bsky.social · 10/02/2025

Now open access in NDT Disease-modifying anti-nephropathic drugs (DMANDs) - A definition from Immunonephrology WG of ERA 1⃣ Disease activity ⬇️ 2⃣ Maintaining kidney structure/function 3⃣ Treatment toxicity ⬇️ ▶️https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaf033/8005963?login=false

021

Hans-Joachim Anders @hjanders.bsky.social · 04/02/2025

Now open access in @ndt-era.bsky.social Obinutuzumab for the management of immune-mediated glomerular diseases 🧐Obinutuzumab holds great potential as novel first-line therapeutic option for various immune-mediated glomerular diseases ▶️academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf021/7997681

052

Hans-Joachim Anders @hjanders.bsky.social · 03/02/2025

Now open access in Nature Reviews DiseasePrimers Chronic Kidney Disease All you need to know about CKD and how to halt CKD progression rdcu.be/d71Rj

020